<DOC>
	<DOCNO>NCT00691392</DOCNO>
	<brief_summary>This one-period , double-blind , single-center pharmacokinetic study linezolid patient MDR XDR tuberculosis treat linezolid Optimized Background Therapy ( define treatment &gt; 4 drug activity tuberculosis patient 's isolate believe sensitive history base drug sensitivity test ) .</brief_summary>
	<brief_title>Linezolid Pharmacokinetics ( PK ) Multi-Drug Resistant ( MDR ) /Extensively-Drug Resistant ( XDR ) Tuberculosis ( TB )</brief_title>
	<detailed_description>This one-period , double-blind , single-center pharmacokinetic study linezolid patient MDR XDR tuberculosis treat linezolid Optimized Background Therapy ( define treatment &gt; 4 drug activity tuberculosis patient 's isolate believe sensitive history base drug sensitivity test ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Enrolled TBTC Study 30 Provision inform consent study Severe anemia define hematocrit le 25 % ( recent value , measure within 30 day PK study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Multi-Drug Resistant Tuberculosis</keyword>
	<keyword>Extensively Drug Resistant Tuberculosis</keyword>
	<keyword>MDR TB</keyword>
	<keyword>XDR TB</keyword>
	<keyword>MDR</keyword>
	<keyword>XDR</keyword>
</DOC>